{"schema_version":"secwatch.filing_event.v1","accession":"0001100682-24-000033","form_type":"8-K","ticker":"CRL","cik":"0001100682","company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.667929+00:00","generated_at":"2026-05-30T04:19:00.540521+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Charles River Q3 revenue $1.01B (-1.6% YoY); non-GAAP EPS $2.59 beats prior outlook; narrows FY guidance","bullets":["Revenue $1.01B, down 1.6% YoY (organic -2.7%); GAAP EPS $1.33, non-GAAP EPS $2.59.","DSA segment organic revenue fell 7.4%; Manufacturing organic revenue grew 11.8%.","Board approved $1B stock repurchase; $100.7M spent in Q3, $899.3M remaining.","FY 2024 guidance narrowed: reported revenue (3%)-(2%); non-GAAP EPS raised to $10.10-$10.30.","CEO cites stable demand indicators and biotech funding improvement; restructuring actions continue."],"urls":{"canonical":"https://secwatch.observer/filing/0001100682-24-000033","json":"https://secwatch.observer/filing/0001100682-24-000033.json","markdown":"https://secwatch.observer/filing/0001100682-24-000033.md","text":"https://secwatch.observer/filing/0001100682-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100682/000110068224000033/0001100682-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100682/000110068224000033/crl-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:19:00.540521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}